MDR1 and OPRM1 genetic polymorphisms on the pharmacodynamics of propofol-remifentanil TIVA in pediatrics.
Liew YeeFrancis R CapuleRaha Abdul RahmanNadia Md NorRufinah TeoMohd Makmor BakryPublished in: Pharmacogenomics (2023)
Aims: To investigate the roles of MDR1 ( 1236C>T, 2677G>T/A , and 3435C>T ) and OPRM1 ( 118A>G ) gene polymorphisms on the anesthetic and adverse effects of propofol-remifentanil total intravenous anesthesia in pediatric surgery. Materials & methods: The genotypes were identified through Sanger sequencing. The clinical data including hemodynamics on anesthesia, postanesthesia pain and sedation score and the occurrence of adverse effects were recorded and compared against the genetic data. Results: A total of 72 pediatric patients undergoing surgery were recruited. A weak to no association was found between the genetic polymorphisms of MDR1 and OPRM1 and the anesthetic and adverse effects of propofol-remifentanil. Conclusion: Genetic polymorphisms in OPRM1 , but not in MDR1 , gene polymorphism, demonstrated plausible association with the effects of propofol-remifentanil.
Keyphrases
- multidrug resistant
- minimally invasive
- coronary artery bypass
- patients undergoing
- electronic health record
- big data
- surgical site infection
- neuropathic pain
- risk assessment
- single cell
- emergency department
- high dose
- pain management
- intensive care unit
- genome wide
- young adults
- acute respiratory distress syndrome
- data analysis
- artificial intelligence
- deep learning
- high throughput sequencing